Form 8-K - Current report:
SEC Accession No. 0001558370-25-001693
Filing Date
2025-02-27
Accepted
2025-02-27 08:03:38
Documents
15
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K qure-20250227x8k.htm   iXBRL 8-K 36530
2 EX-99.1 qure-20250227xex99d1.htm EX-99.1 184406
3 GRAPHIC qure-20250227xex99d1001.jpg GRAPHIC 5856
  Complete submission text file 0001558370-25-001693.txt   361557

Data Files

Seq Description Document Type Size
4 EX-101.SCH qure-20250227.xsd EX-101.SCH 3266
5 EX-101.LAB qure-20250227_lab.xml EX-101.LAB 15218
6 EX-101.PRE qure-20250227_pre.xml EX-101.PRE 9968
17 EXTRACTED XBRL INSTANCE DOCUMENT qure-20250227x8k_htm.xml XML 4645
Mailing Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP 1-339-970-7000
uniQure N.V. (Filer) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36294 | Film No.: 25673130
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)